Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | RAD52 | P43351 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 2/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29789697 | 0.79 | MAPT (0.50) | GAAMAPTALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL2255782 | 0.79 | MAPT (0.50) | GAAMAPTALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL1726909 | 0.76 | GAA (0.46) | GAAMAPTALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL6607968 | 0.76 | GAA (0.46) | GAAMAPTALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL1285713 | 0.76 | MAPT (0.46) | GAAMAPTALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL2125224 | 0.73 | GAA (0.43) | GAAMAPTALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL11026821 | 0.73 | GAA (0.43) | GAAMAPTALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL20338494 | 0.73 | GAA (0.43) | GAAMAPTALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL29976025 | 0.73 | GAA (0.43) | GAAMAPTALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL7159138 | 0.71 | MAPT (0.45) | GAAMAPTALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190218214-A1 | Inhibition of BMP Signaling Compounds, Compositions and Uses Thereof | VANDERBILT UNIVERSITY | 2019-07-18 | — | — | US | disclosed |
| CN-104356006-B | Benzylamine, their preparation method and they as anti-inflammatory agent purposes | 拜耳知识产权有限责任公司 | 2017-09-29 | — | — | CN | disclosed |
| CN-101522197-B | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA NV | 2013-12-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218214-A1 | Inhibition of BMP Signaling Compounds, Compositions and Uses Thereof | BMP1, BMP4, BMP2 | GAA 3794/4885MAPT 4306/4885ALDH1A1 3909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.